Mouse PD-L1/B7-H1 PicoKine ELISA Kit
To Order Contact us: [email protected]
PD-L1/B7-H1/CD274 (C-mFc) |
|||
| E21-M06 | EnoGene | 10ug | EUR 343 |
PD-L1/B7-H1/CD274 (C-Flag) |
|||
| E21-M33 | EnoGene | 10ug | EUR 343 |
PD-L1/B7-H1/CD274(Fc fusion) |
|||
| E21-M79 | EnoGene | 10ug | EUR 343 |
Polyclonal B7-H1 / PD-L1 / CD274 Antibody |
|||
| APR03374G | Leading Biology | 0.05ml | EUR 484 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human B7-H1 / PD-L1 / CD274 . This antibody is tested and proven to work in the following applications: |
|||
Anti-PD-L1/B7-H1/CD274 Antibody |
|||
| A00109 | BosterBio | 100ug/vial | EUR 294 |
CD274 [B7-H1/PD-L1] Recombinant Protein |
|||
| 90-429 | ProSci | 100 ug | EUR 542.75 |
|
Description: Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. CD274 has been identified as one of two ligands for programmed death 1 (PD-1), a member of the CD28 family of immunoreceptors. CD274 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. CD274 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. CD274 expression is also induced in dendritic cells and keratinocytes after IFN-gamma stimulation. CD274 expression is also upregulated in a variety of tumor cell lines. Interaction of CD274 with PD-1 results in inhibition of TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. The CD274 - PD-1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance. |
|||
CD274 [B7-H1/PD-L1] Recombinant Protein |
|||
| 90-431 | ProSci | 100 ug | EUR 542.75 |
|
Description: Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. CD274 has been identified as one of two ligands for programmed death 1 (PD-1), a member of the CD28 family of immunoreceptors. CD274 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. CD274 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. CD274 expression is also induced in dendritic cells and keratinocytes after IFN-gamma stimulation. CD274 expression is also upregulated in a variety of tumor cell lines. Interaction of CD274 with PD-1 results in inhibition of TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. The CD274 - PD-1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance. |
|||
Recombinant Mouse PD-L1/B7-H1/CD274 (C-6His) |
|||
| CJ88-10ug | Novoprotein | 10ug | EUR 100 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Mouse PD-L1/B7-H1/CD274 (C-6His) |
|||
| CJ88-1mg | Novoprotein | 1mg | EUR 1115 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Mouse PD-L1/B7-H1/CD274 (C-6His) |
|||
| CJ88-500ug | Novoprotein | 500ug | EUR 709 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Mouse PD-L1/B7-H1/CD274 (C-6His) |
|||
| CJ88-50ug | Novoprotein | 50ug | EUR 156 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Mouse PD-L1/B7-H1/CD274 (C-Fc) |
|||
| CJ89-10ug | Novoprotein | 10ug | EUR 100 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Mouse PD-L1/B7-H1/CD274 (C-Fc) |
|||
| CJ89-1mg | Novoprotein | 1mg | EUR 1115 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Mouse PD-L1/B7-H1/CD274 (C-Fc) |
|||
| CJ89-500ug | Novoprotein | 500ug | EUR 709 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Recombinant Mouse PD-L1/B7-H1/CD274 (C-Fc) |
|||
| CJ89-50ug | Novoprotein | 50ug | EUR 156 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
|||
Human CellExp? PD-L1 /CD274 /B7-H1, mouse recombinant |
|||
| 7428-10 | Biovision | EUR 278 | |
Human CellExp? PD-L1 /CD274 /B7-H1, mouse recombinant |
|||
| 7428-50 | Biovision | EUR 718 | |
Recombinant Rat PD-L1/B7-H1/CD274 Protein |
|||
| RP00800 | Abclonal | 10 μg | EUR 174 |
PD-L1 / B7-H1 (19-134) Recombinant Protein |
|||
| 11-114 | ProSci | 0.1 mg | EUR 595.25 |
|
Description: Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. |
|||
Recombinant Human PD-L1/B7-H1/CD274 (C-mFc) |
|||
| CM06-10ug | Novoprotein | 10ug | EUR 115 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274 (C-mFc) |
|||
| CM06-1mg | Novoprotein | 1mg | EUR 1674 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274 (C-mFc) |
|||
| CM06-500ug | Novoprotein | 500ug | EUR 1186 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274 (C-mFc) |
|||
| CM06-50ug | Novoprotein | 50ug | EUR 202 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274 (C-Flag) |
|||
| CM33-10ug | Novoprotein | 10ug | EUR 115 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB 150mM Nacl pH 7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274 (C-Flag) |
|||
| CM33-1mg | Novoprotein | 1mg | EUR 1674 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB 150mM Nacl pH 7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274 (C-Flag) |
|||
| CM33-500ug | Novoprotein | 500ug | EUR 1186 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB 150mM Nacl pH 7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274 (C-Flag) |
|||
| CM33-50ug | Novoprotein | 50ug | EUR 202 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB 150mM Nacl pH 7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274(C-Fc) |
|||
| CM79-10ug | Novoprotein | 10ug | EUR 115 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274(C-Fc) |
|||
| CM79-1mg | Novoprotein | 1mg | EUR 1674 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274(C-Fc) |
|||
| CM79-500ug | Novoprotein | 500ug | EUR 1186 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274(C-Fc) |
|||
| CM79-50ug | Novoprotein | 50ug | EUR 202 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274 (C-6His) |
|||
| C315-10ug | Novoprotein | 10ug | EUR 90 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 5% Trehalose, pH 7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274 (C-6His) |
|||
| C315-1mg | Novoprotein | 1mg | EUR 1166 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 5% Trehalose, pH 7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274 (C-6His) |
|||
| C315-500ug | Novoprotein | 500ug | EUR 831 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 5% Trehalose, pH 7.4. |
|||
Recombinant Human PD-L1/B7-H1/CD274 (C-6His) |
|||
| C315-50ug | Novoprotein | 50ug | EUR 171 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 5% Trehalose, pH 7.4. |
|||
Anti-PD-L1 (CD274) (B7-H1), Rabbit Monoclonal Antibody |
|||
| A1824-50 | Biovision | Ask for price | |
Human CellExp? PD-L1 /CD274 /B7-H1, human recombinant |
|||
| 7429-10 | Biovision | EUR 224 | |
Human CellExp? PD-L1 /CD274 /B7-H1, human recombinant |
|||
| 7429-1000 | Biovision | Ask for price | |
Human CellExp? PD-L1 /CD274 /B7-H1, human recombinant |
|||
| 7429-250 | Biovision | EUR 2159 | |
Human CellExp? PD-L1 /CD274 /B7-H1, human recombinant |
|||
| 7429-50 | Biovision | EUR 604 | |
CD274 [B7-H1/PD-L1] non-lytic Recombinant Protein |
|||
| 90-430 | ProSci | 100 ug | EUR 542.75 |
|
Description: Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. CD274 has been identified as one of two ligands for programmed death 1 (PD-1), a member of the CD28 family of immunoreceptors. CD274 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. CD274 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. CD274 expression is also induced in dendritic cells and keratinocytes after IFN-gamma stimulation. CD274 expression is also upregulated in a variety of tumor cell lines. Interaction of CD274 with PD-1 results in inhibition of TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. The CD274 - PD-1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance. |
|||
CD274 [B7-H1/PD-L1] non-lytic Recombinant Protein |
|||
| 90-432 | ProSci | 100 ug | EUR 542.75 |
|
Description: Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. CD274 has been identified as one of two ligands for programmed death 1 (PD-1), a member of the CD28 family of immunoreceptors. CD274 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. CD274 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. CD274 expression is also induced in dendritic cells and keratinocytes after IFN-gamma stimulation. CD274 expression is also upregulated in a variety of tumor cell lines. Interaction of CD274 with PD-1 results in inhibition of TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. The CD274 - PD-1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance. |
|||
Mouse PD-L1/B7-H1 EZ-Set™ ELISA Kit (DIY Antibody Pairs) |
|||
| EZ1450 | BosterBio | 5 plates/kit | EUR 324 |
|
Description: NA |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1; Clone PDL1/2746 (Concentrate) |
|||
| RA0501-C.1 | ScyTek Laboratories | 0.1 ml | EUR 125 |
PD-L1 / PDCD1LG1 / CD274 / B7-H1; Clone PDL1/2746 (Concentrate) |
|||
| RA0501-C.5 | ScyTek Laboratories | 0.5 ml | EUR 300 |
PD-L1 / PDCD1LG1 / CD274 / B7-H1; Clone PDL1/2746 (Concentrate) |
|||
| RA0501-C1 | ScyTek Laboratories | 1 ml | EUR 500 |
Human Programmed Death Ligand 1 ELISA Kit (PD-L1/B7-H1/ CD274) |
|||
| RK04115 | Abclonal | 96 Tests | EUR 606 |
Rat Anti-Mouse PD-L1 (B7-H1) Monoclonal antibody, clone 10F.9G2 |
|||
| CABT-L4404-1mg | Creative Diagnostics | 1 mg | EUR 897 |
Rat Anti-Mouse PD-L1 (B7-H1) Monoclonal antibody, clone 10F.9G2 |
|||
| CABT-L4404-5mg | Creative Diagnostics | 5 mg | EUR 2405 |
Mouse Anti-Human PD-L1 (B7-H1) Monoclonal antibody, clone 29E.2A3 |
|||
| CABT-L4518-1mg | Creative Diagnostics | 1 mg | EUR 897 |
Mouse Anti-Human PD-L1 (B7-H1) Monoclonal antibody, clone 29E.2A3 |
|||
| CABT-L4518-5mg | Creative Diagnostics | 5 mg | EUR 2405 |
Anti-PD-L1 (CD274) (B7-H1) Rabbit Monoclonal Antibody, Clone#RM320 |
|||
| M00109-1 | BosterBio | 100uL | EUR 427 |
|
Description: Anti-PD-L1 (CD274) (B7-H1) Rabbit Monoclonal Antibody, Clone#RM320 tested in WB, IHC, reactive to Human |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC432746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF543 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC432746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF543 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC472746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF647 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC472746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF647 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCAP2746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCAP2746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC802746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC802746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC682746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF568 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC682746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF568 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC812746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC812746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC882746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF488A conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC882746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF488A conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC612746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF660R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC612746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF660R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC942746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC942746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCA2746-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), APC conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNUB2746-100 | Biotium | 100uL | EUR 264 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Concentration: 0.2mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNUB2746-500 | Biotium | 500uL | EUR 513 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Concentration: 0.2mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNUM2746-50 | Biotium | 50uL | EUR 405 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), 1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCH2746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCH2746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC042746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405S conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC042746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405S conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC052746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405M conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC052746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405M conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCP2746-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), PerCP conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCR2746-250 | Biotium | 250uL | EUR 394 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), RPE conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC402746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF640R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC402746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF640R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCB2746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Biotin conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNCB2746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Biotin conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC552746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF555 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC552746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF555 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC702746-100 | Biotium | 100uL | EUR 233 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF770 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
| BNC702746-500 | Biotium | 500uL | EUR 545 |
|
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF770 conjugate, Concentration: 0.1mg/mL |
|||